JP2016510033A5 - - Google Patents

Download PDF

Info

Publication number
JP2016510033A5
JP2016510033A5 JP2015560337A JP2015560337A JP2016510033A5 JP 2016510033 A5 JP2016510033 A5 JP 2016510033A5 JP 2015560337 A JP2015560337 A JP 2015560337A JP 2015560337 A JP2015560337 A JP 2015560337A JP 2016510033 A5 JP2016510033 A5 JP 2016510033A5
Authority
JP
Japan
Prior art keywords
phenyl
pyrazol
methoxy
amino
propanamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015560337A
Other languages
English (en)
Japanese (ja)
Other versions
JP6423372B2 (ja
JP2016510033A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/019242 external-priority patent/WO2014134391A1/en
Publication of JP2016510033A publication Critical patent/JP2016510033A/ja
Publication of JP2016510033A5 publication Critical patent/JP2016510033A5/ja
Application granted granted Critical
Publication of JP6423372B2 publication Critical patent/JP6423372B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015560337A 2013-02-28 2014-02-28 強力なrock1およびrock2阻害剤としてのフェニルピラゾール誘導体 Expired - Fee Related JP6423372B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361770531P 2013-02-28 2013-02-28
US61/770,531 2013-02-28
PCT/US2014/019242 WO2014134391A1 (en) 2013-02-28 2014-02-28 Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors

Publications (3)

Publication Number Publication Date
JP2016510033A JP2016510033A (ja) 2016-04-04
JP2016510033A5 true JP2016510033A5 (enExample) 2017-03-09
JP6423372B2 JP6423372B2 (ja) 2018-11-14

Family

ID=50382571

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015560337A Expired - Fee Related JP6423372B2 (ja) 2013-02-28 2014-02-28 強力なrock1およびrock2阻害剤としてのフェニルピラゾール誘導体

Country Status (5)

Country Link
US (1) US9828345B2 (enExample)
EP (1) EP2961746B1 (enExample)
JP (1) JP6423372B2 (enExample)
CN (1) CN105102448B (enExample)
WO (1) WO2014134391A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR094929A1 (es) 2013-02-28 2015-09-09 Bristol Myers Squibb Co Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
US9902702B2 (en) 2014-07-15 2018-02-27 Bristol-Myers Squibb Company Spirocycloheptanes as inhibitors of rock
JP6633618B2 (ja) 2014-08-21 2020-01-22 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 強力なrock阻害剤としてのタイドバックのベンズアミド誘導体
WO2016112236A1 (en) * 2015-01-09 2016-07-14 Bristol-Myers Squibb Company Cyclic ureas as inhibitors of rock
WO2016144936A1 (en) * 2015-03-09 2016-09-15 Bristol-Myers Squibb Company Lactams as inhibitors of rock
AR107354A1 (es) 2016-01-13 2018-04-18 Bristol Myers Squibb Co Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock
JP6987792B2 (ja) * 2016-05-27 2022-01-05 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Rock阻害剤としてのトリアゾロンおよびテトラゾロン
ES2821877T3 (es) * 2016-07-07 2021-04-28 Bristol Myers Squibb Co Espirolactamas como inhibidores de ROCK
CN110049977B (zh) 2016-07-07 2022-01-18 百时美施贵宝公司 作为强效和选择性rock抑制剂的内酰胺、环状脲和氨基甲酸酯及三唑酮衍生物
ES2829550T3 (es) * 2016-07-07 2021-06-01 Bristol Myers Squibb Co Ureas cíclicas espiro-condensadas como inhibidores de ROCK
KR102511441B1 (ko) * 2016-11-30 2023-03-16 브리스톨-마이어스 스큅 컴퍼니 트리시클릭 Rho 키나제 억제제
JP7206253B2 (ja) 2017-07-12 2023-01-17 ブリストル-マイヤーズ スクイブ カンパニー Rock阻害剤としてのフェニルアセトアミド
TW201908293A (zh) 2017-07-12 2019-03-01 美商必治妥美雅史谷比公司 作為rock抑制劑之5員及雙環雜環醯胺
KR102680160B1 (ko) 2017-07-12 2024-06-28 브리스톨-마이어스 스큅 컴퍼니 심부전의 치료를 위한 rock의 5원-아미노헤테로사이클 및 5,6- 또는 6,6-원 비시클릭 아미노헤테로시클릭 억제제
US12060341B2 (en) 2017-07-12 2024-08-13 Bristol-Myers Squibb Company Spiroheptanyl hydantoins as ROCK inhibitors
JP7313331B2 (ja) 2017-07-12 2023-07-24 ブリストル-マイヤーズ スクイブ カンパニー Rock阻害剤としてのスピロヘプタニルヒダントイン
EA202090306A1 (ru) * 2017-07-21 2020-06-25 Кадмон Корпорейшн, Ллк ИНГИБИТОРЫ Rho-АССОЦИИРОВАННОЙ, СОДЕРЖАЩЕЙ СУПЕРСПИРАЛЬ ПРОТЕИНКИНАЗЫ
WO2019089868A1 (en) 2017-11-03 2019-05-09 Bristol-Myers Squibb Company Diazaspiro rock inhibitors
TWI777325B (zh) * 2019-12-31 2022-09-11 財團法人工業技術研究院 β-胺基酸衍生物、含其之激酶抑制劑與醫藥組成物以及其用途
US12014835B2 (en) 2020-02-19 2024-06-18 Vanderbilt University Methods for evaluating therapeutic benefit of combination therapies

Family Cites Families (192)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59310252D1 (de) 1992-02-05 2002-01-24 Boehringer Ingelheim Pharma Neue Amiderivate, ihre Herstellung und Verwendung als Arzneimittel mit LTB4-antagonistischer Wirkung
CA2136999C (en) 1993-04-07 2004-05-11 Takafumi Fujioka Peripheral vasodilating agent containing piperidine derivative as active ingredient
NZ277556A (en) 1993-12-27 1997-06-24 Eisai Co Ltd N-phenyl(alkyl)- and n-pyridyl(alkyl)anthranilic acid derivatives; intermediates
GB9500580D0 (en) 1995-01-12 1995-03-01 Merck Sharp & Dohme Therapeutic agents
US5763618A (en) 1995-05-12 1998-06-09 Konica Corporation Manufacturing method of sulfides
DE19545878A1 (de) 1995-12-08 1997-06-12 Basf Ag Pyridylcarbamate, Verfahren und Zwischenprodukte zu ihrer Herstellung und ihre Verwendung
DE69717268T2 (de) 1996-02-22 2003-09-04 Bristol-Myers Squibb Pharma Co., Wilmington M-amidinophenyl-analoga als faktor-xa-inhibitoren
WO1997036886A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CN1246847A (zh) 1996-12-23 2000-03-08 杜邦药品公司 作为Xa因子抑制剂的含氮杂芳族化合物
US6187797B1 (en) 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
US6020357A (en) 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
ES2196396T3 (es) 1996-12-23 2003-12-16 Bristol Myers Squibb Pharma Co Compuestos heteroaromaticos de 5 miembros conteniendo oxigeno o azufre como inhibidores del factor xa.
HUP0003906A2 (hu) 1997-06-19 2001-05-28 Du Pont Pharmaceuticals Co. Xa faktort gátló hatású heterociklusos vegyületek és ezeket tartalmazó gyógyszerkészítmények
US6339099B1 (en) 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
EP1000059B1 (en) 1997-07-30 2004-09-29 Wyeth Tricyclic vasopressin agonists
US6511974B1 (en) 1997-07-30 2003-01-28 Wyeth Tricyclic vasopressin agonists
JP4338305B2 (ja) 1997-07-30 2009-10-07 ワイス 三環系バソプレシンアゴニスト
EP1076641A1 (en) 1998-04-29 2001-02-21 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
US6121271A (en) 1998-05-12 2000-09-19 American Home Products Corporation Naphtho[2,3-B]heteroar-4-yl derivatives
EP1077968A1 (en) 1998-05-12 2001-02-28 American Home Products Corporation Naphtho[2,3-b]heteroar-4-yl derivatives
JP2000109465A (ja) * 1998-08-05 2000-04-18 Nippon Soda Co Ltd フェニルピラゾ―ル化合物、製法及び抗高脂血症薬
EP1127054A4 (en) 1998-10-29 2006-11-02 Bristol Myers Squibb Co INHIBITORS OF IMPDH ENZYME
WO2000029399A1 (en) 1998-11-12 2000-05-25 Boehringer Ingelheim (Canada) Ltd. Antiherpes compounds
PT1149096E (pt) 1999-02-04 2003-03-31 Wyeth Corp N-oxidos de piridina triciclicos agonistas de vasopressina
JP2000256358A (ja) 1999-03-10 2000-09-19 Yamanouchi Pharmaceut Co Ltd ピラゾール誘導体
PT1177187E (pt) 1999-04-28 2007-09-03 Sanofi Aventis Deutschland Derivados ácidos de di-arilo como ligados do receptor ppar.
MXPA02003191A (es) 1999-09-27 2002-09-30 American Cyanamid Co Formulacion agonista de vasopresina y proceso para elaborar la misma.
ATE376996T1 (de) 2000-01-13 2007-11-15 Amgen Inc Antibakterielle mittel
AU2001243598A1 (en) 2000-03-13 2001-09-24 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
MY138097A (en) 2000-03-22 2009-04-30 Du Pont Insecticidal anthranilamides
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
DE10063008A1 (de) 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
AU2002248432A1 (en) 2001-02-14 2002-08-28 Sankyo Company, Limited Oxazole derivatives, their preparation and their use as cytokine inhibitors
CA2437840A1 (en) 2001-03-05 2002-09-12 E.I. Du Pont De Nemours Heterocyclic diamide invertebrate pest control agents
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10111842A1 (de) 2001-03-13 2002-09-19 Boehringer Ingelheim Pharma Antithrombotische Carbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel
WO2002076959A1 (en) 2001-03-23 2002-10-03 Takeda Chemical Industries, Ltd. Five-membered heterocyclic alkanoic acid derivative
CA2447475A1 (en) 2001-05-25 2002-12-05 Chu-Biao Xue Hydantion derivatives as inhibitors of matrix metalloproteinases
DE10130374A1 (de) 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Substituierte N-Acyl-anilinderivate, deren Herstellung und deren Verwendung als Arzneimittel
PL367677A1 (en) 2001-06-28 2005-03-07 Smithkline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
WO2003004474A1 (en) 2001-07-06 2003-01-16 Syngenta Participations Ag Pesticidally active aminoacetonitriles
MXPA04001088A (es) 2001-08-03 2004-05-20 Vertex Pharma Derivados de pirazol como inhibidores de cinasa y uso de los mismos.
GB0124463D0 (en) 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
SE0103644D0 (sv) 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic isoquinoline compounds
US6984735B2 (en) 2001-12-03 2006-01-10 Wyeth Process for making an aldehyde
AU2003220401A1 (en) 2002-03-18 2003-10-08 Bristol-Myers Squibb Company Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases
EP1487796A4 (en) 2002-03-28 2005-11-16 Neurogen Corp SUBSTITUTED BIARYLAMIDES AS MODULATORS OF THE C5A RECEPTOR
WO2004000788A1 (en) 2002-06-19 2003-12-31 Bristol-Myers Squibb Company Ureido-substituted aniline compounds useful as serine protease inhibitors
US20040044041A1 (en) 2002-08-06 2004-03-04 Kuduk Scott D. 2-(Biarylalkyl)amino-3-(cyanoalkanoylamino)pyridine derivatives
WO2004016592A1 (en) 2002-08-14 2004-02-26 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
WO2004033632A2 (en) 2002-10-04 2004-04-22 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)
US20040082641A1 (en) 2002-10-28 2004-04-29 Rytved Klaus Asger Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
CA2505361A1 (en) 2002-11-11 2004-05-27 Bayer Healthcare Ag Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist
JP2004161716A (ja) 2002-11-15 2004-06-10 Takeda Chem Ind Ltd Jnk阻害剤
EP1594512A4 (en) 2003-02-11 2007-07-11 Kemia Inc COMPOUNDS FOR THE TREATMENT OF VIRUS INFECTIONS
DE10306250A1 (de) 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EA200501607A1 (ru) 2003-04-14 2006-06-30 ДЗЕ ИНСТИТЬЮТС ФОР ФАРМАСЬЮТИКАЛ ДИСКАВЕРИ, ЭлЭлСи Замещённые фенилалкановые кислоты
WO2005000813A1 (en) 2003-05-30 2005-01-06 Imclone Systems Incorporated Heteroarylamino-phenylketone derivatives and their use as kinase inhibitors
CA2534263A1 (en) 2003-08-01 2005-02-10 Nippon Soda Co., Ltd. Phenylazole compounds, production process and antioxidants
BRPI0413785A (pt) 2003-08-21 2006-11-07 Osi Pharm Inc composto, composição, e, método de tratamento de distúrbio hiperproliferativo
US7485658B2 (en) 2003-08-21 2009-02-03 Osi Pharmaceuticals, Inc. N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors
EP1663204B1 (en) 2003-08-29 2014-05-07 Exelixis, Inc. C-kit modulators and methods of use
EP1786815B1 (en) 2003-09-10 2011-08-24 Virochem Pharma Inc. Spiro compounds and methods for the modulation of chemokine receptor activity
US7211671B2 (en) 2003-10-01 2007-05-01 Bristol Myers Squibb Company Substituted 1,3-dihydro-imidazol-2-one and 1,3-dihydro-imidazol-2-thione derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
CA2541458C (en) 2003-10-08 2011-09-20 Eli Lilly And Company Pyrrole and pyrazole derivatives as potentiators of glutamate receptors
WO2005039494A2 (en) 2003-10-21 2005-05-06 Message Pharmaceuticals, Inc. Inhibitors of rnase p proteins as antibacterial compounds
EP1713775A4 (en) * 2004-01-30 2009-08-12 Smithkline Beecham Corp CHEMICAL COMPOUNDS
EP1574502A1 (en) 2004-03-08 2005-09-14 Novartis AG Use of pyrimidine compounds in the preparation of parasiticides
JP2008512378A (ja) 2004-09-03 2008-04-24 セルジーン・コーポレーション 置換複素環式化合物及びその使用
CA2585555A1 (en) 2004-10-28 2006-05-11 The Institutes For Pharmaceutical Discovery, Llc Substituted phenylalkanoic acids
WO2006068933A2 (en) 2004-12-21 2006-06-29 Merck & Co., Inc. Mitotic kinesin inhibitors
US8329703B2 (en) 2005-02-15 2012-12-11 Xtl Biopharmaceuticals Ltd. Pyrazole compounds
EP1863756A1 (en) 2005-03-24 2007-12-12 Janssen Pharmaceutica N.V. Biaryl derived amide modulators of vanilloid vr1 receptor
FR2887548B1 (fr) 2005-06-27 2007-09-21 Sanofi Aventis Sa Derives de 4,5-diarylpyrrole, leur preparation et leur application en therapeutique
US8569352B2 (en) 2005-06-27 2013-10-29 Exelixis Patent Company Llc Imidazole based LXR modulators
FR2888237B1 (fr) 2005-07-08 2007-08-31 Sanofi Aventis Sa Derives de n-[(4,5-diphenylpyrimidin-2-yl)methyl] amine, leur preparation et leur application en therapeutique
AR057450A1 (es) 2005-07-12 2007-12-05 Sanofi Aventis Derivados de n-[(1,2-difenil-1h-imidazol-4- il)metil]amina su preparacion y su aplicacion en terapeutica
MX2008002540A (es) 2005-08-23 2008-03-14 Irm Llc Compuestos inmunosupresores y composiciones.
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
FR2894579B1 (fr) 2005-12-12 2008-01-18 Sanofi Aventis Sa Derives diaryltriazolmethylamine, leur preparation et leur application en therapeutique.
FR2894578B1 (fr) 2005-12-12 2008-02-01 Sanofi Aventis Sa Derives heterocycliques, leur preparation et leur application en therapeutique.
EP1971602A4 (en) 2005-12-20 2009-11-11 Merck & Co Inc AGONISTS OF THE NIACIN RECEPTOR, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND TREATMENT PROCEDURES
KR20080083680A (ko) 2005-12-23 2008-09-18 스미스클라인 비참 코포레이션 오로라 키나제의 아자인돌 억제제
WO2007098169A1 (en) 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
AU2012200157B2 (en) 2006-05-25 2014-08-21 Synta Pharmaceuticals Corp. Method for treating proliferative disorders associated with protooncogene products
WO2007146230A2 (en) 2006-06-14 2007-12-21 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
MX2008015923A (es) 2006-06-29 2009-01-13 Hoffmann La Roche Derivados de bencimidazol, metodo para su produccion, su uso como agonistas fxr y preparaciones farmaceuticas que los contienen.
BRPI0712795A2 (pt) 2006-07-07 2012-09-04 Boehringer Ingelheim Int derivados de heteroarila substituìdos com fenila e uso dos mesmos como agentes antitumorais
WO2008016643A2 (en) 2006-08-01 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
FR2904827B1 (fr) 2006-08-11 2008-09-19 Sanofi Aventis Sa Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antiganistes des recepteurs a l'urotensine ii
AU2007294149A1 (en) 2006-09-06 2008-03-13 F. Hoffmann-La Roche Ag Heteroaryl derivatives as protein kinase inhibitors
WO2008057246A2 (en) 2006-10-26 2008-05-15 Synta Pharmaceuticals Corp. Method for treating inflammatory disorders
WO2008064317A1 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Lipophilic opioid receptor active compounds
WO2008064318A2 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Peripheral opioid receptor active compounds
WO2008064310A2 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Mixed opioid receptor active compounds
ES2401129T3 (es) 2006-12-19 2013-04-17 F. Hoffmann-La Roche Ag Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona
EP2079694B1 (en) 2006-12-28 2017-03-01 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
FR2911136B1 (fr) 2007-01-05 2009-02-20 Sanofi Aventis Sa Derives de n-(4-cyano-1h-pyrazol-3-yl)methylamine substitues leur preparation et leur application en therapeutique.
CA2674530C (en) 2007-01-12 2014-09-16 Banyu Pharmaceutical Co., Ltd. Spirochromanon derivatives
TW200838516A (en) 2007-01-31 2008-10-01 Merck & Co Inc Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
JP2008195655A (ja) 2007-02-14 2008-08-28 Kitasato Institute 糖尿病白内障の治療剤
WO2008137102A2 (en) 2007-05-04 2008-11-13 Torreypines Therapeutics, Inc. Methods of modulating amyloid beta and compounds useful therefor
EP1992625A1 (en) 2007-05-16 2008-11-19 Sanofi-Aventis Arylamide pyrimidone compounds
AU2008253311A1 (en) 2007-05-18 2008-11-27 Bayer Schering Pharma Aktiengesellshaft Inhibitors of hypoxia inducible factor (HIF) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
HRP20120240T1 (hr) 2007-05-23 2012-04-30 Merck Sharp & Dohme Corp. Piridil piperidin antagonisti receptora za oreksin
AR066834A1 (es) 2007-06-06 2009-09-16 Janssen Pharmaceutica Nv Espirobenzoazepanos como antagonistas de vasopresina, composiciones farmaceuticas que los contienen, proceso de preparacion y usos para el tratamiento de afecciones cardiacas, renales y del sistema nervioso central.
EP2002838A1 (de) 2007-06-13 2008-12-17 Bayer Schering Pharma AG Verwendung von Aryl/Hetarylamid-Derivaten als Modulatoren des EP2-Rezeptors
WO2008152138A2 (de) 2007-06-15 2008-12-18 Basf Se Verfahren zur herstellung difluormethylsubstituierter pyrazolverbindungen
EP2176249A2 (en) 2007-07-02 2010-04-21 Boehringer Ingelheim International GmbH New chemical compounds
WO2009015208A1 (en) 2007-07-23 2009-01-29 Replidyne, Inc. Antibacterial amide and sulfonamide substituted heterocyclic urea compounds
US20090053192A1 (en) 2007-08-10 2009-02-26 Burnham Institute For Medical Research Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof
EP2193119B1 (en) 2007-08-27 2014-01-01 Abbvie Deutschland GmbH & Co. KG 4-(4-pyridinyl)-benzamides and their use as rock activity modulators
TW200920357A (en) 2007-09-10 2009-05-16 Curis Inc HSP90 inhibitors containing a zinc binding moiety
WO2009036051A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Bcl-2 inhibitors containing a zinc binding moiety
KR20090033583A (ko) 2007-10-01 2009-04-06 주식회사 엘지생명과학 글라이신 아릴 아마이드를 포함하는 신규한베타-세크리타제 저해용 화합물
CA2702482C (en) 2007-10-17 2012-11-27 Sanofi-Aventis Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
TWI440638B (zh) 2007-10-30 2014-06-11 Otsuka Pharma Co Ltd 雜環化合物及其藥學組成物
US20100280049A1 (en) 2007-11-06 2010-11-04 Amira Pharmaceuticals, Inc. Antagonists of pgd2 receptors
CN101945868A (zh) 2007-12-11 2011-01-12 先灵公司 γ分泌酶调节剂
WO2009079008A1 (en) * 2007-12-19 2009-06-25 Yangbo Feng Benzopyrans and analogs as rho kinase inhibitors
JP2011507850A (ja) * 2007-12-21 2011-03-10 ザ スクリプス リサーチ インスティチュート Rhoキナーゼインヒビターとしてのアニリドおよびアナログ
CN101538245B (zh) 2008-03-18 2011-02-16 中国科学院上海药物研究所 一类哒嗪酮类化合物及其制备方法和制备药物的用途
CA2721060A1 (en) 2008-04-09 2009-10-15 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2009131173A1 (ja) 2008-04-23 2009-10-29 協和発酵キリン株式会社 2-アミノキナゾリン誘導体
CN102088855A (zh) 2008-05-08 2011-06-08 百时美施贵宝公司 2-芳基甘氨酰胺衍生物
CN101597278B (zh) 2008-06-04 2013-04-17 中国中化股份有限公司 酰胺类化合物及其制备与应用
NZ624345A (en) 2008-06-27 2016-07-29 Celgene Avilomics Res Inc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8623238B2 (en) 2008-06-27 2014-01-07 Transitions Optical, Inc. Mesogenic stabilizers
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
WO2010036316A1 (en) 2008-09-24 2010-04-01 Yangbo Feng Urea and carbamate compounds and analogs as kinase inhibitors
CA2739303A1 (en) 2008-10-01 2010-04-08 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
US8829001B2 (en) 2008-10-10 2014-09-09 The Institute of Pharmacology and Toxicology Academy of Military Medical Science P.L.A. China Dopamine D3 receptor ligands and preparation and medical uses of the same
US8367679B2 (en) 2008-12-09 2013-02-05 Merck Sharp & Dohme Corp. Biaryl carboxamides
CA2746943A1 (en) 2008-12-18 2010-07-15 Boehringer Ingelheim International Gmbh Serotonin 5-ht2b receptor inhibitors
WO2010075290A1 (en) 2008-12-22 2010-07-01 President And Fellows Of Harvard College Unsaturated heterocyclic inhibitors of necroptosis
US8785468B2 (en) 2009-02-13 2014-07-22 Amgen Inc. Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions
JP5688918B2 (ja) 2009-04-28 2015-03-25 大塚製薬株式会社 医薬組成物
WO2010129848A2 (en) 2009-05-08 2010-11-11 Takeda Pharmaceutical Company Limited 2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxamides
CN102573473B (zh) 2009-06-09 2015-05-27 加利福尼亚资本权益有限责任公司 用作hedgehog 信号转导抑制剂的异喹啉、喹啉和喹唑啉衍生物
AR077033A1 (es) 2009-06-11 2011-07-27 Hoffmann La Roche Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas
EP2477625A4 (en) 2009-09-14 2012-10-24 Phusis Therapeutics Inc PHARMACEUTICAL COMPOSITIONS AND FORMULATIONS COMPRISING PLECKSTRINE HOMOLOGY DOMAIN INHIBITORS AND METHODS OF USE
WO2011041593A1 (en) 2009-09-30 2011-04-07 University Of Kansas Novobiocin analogues and treatment of polycystic kidney disease
US8377970B2 (en) 2009-10-08 2013-02-19 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
US8993612B2 (en) 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
CA2778886C (en) 2009-11-10 2014-01-07 Pfizer Inc. N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
CA2778316A1 (en) 2009-11-10 2011-05-19 Pfizer Inc. N-2 pyrazolospiroketone acetyl-coa carboxylase inhibitors
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
HUE038064T2 (hu) 2009-12-18 2018-10-29 Ogeda Sa Pirrolidin karboxilsav származékok, mint G-protein kapcsolat receptor 43 (GPR43) agonistái, gyógyszerészeti készítmény és felhasználási eljárások metabolikus rendellenességek kezelésében
JP2013047188A (ja) 2009-12-24 2013-03-07 Nippon Chemiphar Co Ltd Gpr119作動薬
WO2011088181A1 (en) 2010-01-13 2011-07-21 Tempero Pharmaceuticals, Inc. Compounds and methods
WO2011088031A1 (en) 2010-01-13 2011-07-21 Glaxosmithkline Llc Compounds and methods
MX2012008141A (es) 2010-01-13 2012-08-03 Glaxosmithkline Llc Compuestos y metodos.
US20190192510A1 (en) 2010-02-01 2019-06-27 Nippon Chemiphar Co., Ltd. Gpr119 agonist
US9206125B2 (en) 2010-02-10 2015-12-08 Public University Corporation Yokohama City University Use of compound binding to mSin3B that specifically binds to neuron restrictive silencer factor (NRSF)
WO2011106632A1 (en) 2010-02-26 2011-09-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US8354410B2 (en) 2010-03-11 2013-01-15 Bristol-Meyers Squibb Company Compounds for the treatment of hepatitis C
JP2013522192A (ja) 2010-03-11 2013-06-13 ブリストル−マイヤーズ スクイブ カンパニー C型肝炎の処置のための化合物
WO2011140425A1 (en) 2010-05-06 2011-11-10 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
WO2011156557A2 (en) 2010-06-11 2011-12-15 Thomas James B Compounds active at the neurotensin receptor
US8697911B2 (en) 2010-07-07 2014-04-15 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US9079880B2 (en) 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
JP5749341B2 (ja) 2010-08-20 2015-07-15 ハチソン メディファーマ リミテッド ピロロピリミジン化合物およびその使用
WO2012040444A2 (en) 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Treatment of patients with incipient alzheimer's disease
CN103327972A (zh) 2010-10-11 2013-09-25 里兰斯坦福初级大学理事会 取代的苯甲酰胺及其用途
CN102451178A (zh) 2010-10-29 2012-05-16 中国科学院上海药物研究所 二氢呋喃-2-酮类化合物在制备抗糖尿病及糖脂代谢药物中的用途
WO2012068210A1 (en) 2010-11-18 2012-05-24 Janssen Pharmaceutica Nv Pyridyl-thiazolyl inhibitors of pro-matrix metalloproteinase activation
RU2013127636A (ru) 2010-11-22 2014-12-27 Аллерган, Инк. Новые соединения в качестве модуляторов рецепторов с терапевтической полезностью
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
SG190957A1 (en) 2010-12-01 2013-07-31 Nissan Chemical Ind Ltd Pyrazole compounds having therapeutic effect on multiple myeloma
US9212348B2 (en) 2010-12-01 2015-12-15 Nissan Chemical Industries, Ltd. Method for producing hematopoietic stem cells using pyrazole compounds
BR112013014019A2 (pt) 2010-12-07 2016-09-13 Amira Pharmaceuticals Inc antagonistas do receptor do ácido lisofosfatídico e seus usos
GB201021104D0 (en) 2010-12-13 2011-01-26 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
TWI520964B (zh) 2011-02-02 2016-02-11 維泰克斯製藥公司 作為離子通道調節劑之吡咯并吡-螺環哌啶醯胺
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
AU2012236834B2 (en) 2011-03-28 2015-12-10 Mei Pharma, Inc (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
US9616064B2 (en) 2011-03-30 2017-04-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Rho kinase inhibitors and methods of use
GB201107223D0 (en) 2011-04-29 2011-06-15 Amakem Nv Novel rock inhibitors
WO2012160464A1 (en) 2011-05-26 2012-11-29 Daiichi Sankyo Company, Limited Heterocyclic compounds as protein kinase inhibitors
CN104909997B (zh) 2011-05-26 2017-04-12 Tf化学公司 芳基、杂芳基、o‑芳基和o‑杂芳基碳环糖家族
CA2835281A1 (en) 2011-05-31 2012-12-06 Theravance, Inc. Neprilysin inhibitors
KR20140051942A (ko) 2011-07-12 2014-05-02 에프. 호프만-라 로슈 아게 아미노메틸 퀴놀론 화합물
JP5967092B2 (ja) 2011-07-29 2016-08-10 日本ゼオン株式会社 光学異方体の波長分散調整方法及び重合性組成物
US9365588B2 (en) 2011-11-04 2016-06-14 Vertex Pharmaceuticals Incorporated Benzoxazines as modulators of ion channels
JP6243908B2 (ja) 2012-08-23 2017-12-06 アリオス バイオファーマ インク. パラミクソウイルス感染症を治療するための化合物
WO2014079850A1 (en) 2012-11-23 2014-05-30 F. Hoffmann-La Roche Ag Substituted heterocyclic derivatives
CA2898440A1 (en) 2013-01-18 2014-07-24 Bristol-Myers Squibb Company Phthalazinones and isoquinolinones as rock inhibitors
AR094929A1 (es) 2013-02-28 2015-09-09 Bristol Myers Squibb Co Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
EP3016950B1 (en) 2013-07-02 2017-06-07 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
CN105492444B (zh) 2013-07-02 2018-09-07 百时美施贵宝公司 作为rock抑制剂的三环吡啶-甲酰胺衍生物
RU2016131875A (ru) 2014-01-20 2018-02-26 Ф. Хоффманн-Ля Рош Аг Производные n-фениллактама, способные стимулировать нейрогенез, и их применение при лечении заболеваний нервной системы

Similar Documents

Publication Publication Date Title
JP2016510033A5 (enExample)
JP2019520398A5 (enExample)
JP2016510032A5 (enExample)
JP2019520396A5 (enExample)
HRP20211002T1 (hr) 1,3-tiazol-2-il supstituirani benzamidi
JP2018501285A5 (enExample)
JP2012521994A5 (enExample)
JP2016028076A5 (enExample)
JP2013510122A5 (enExample)
JP2013543896A5 (enExample)
JP2013545785A5 (enExample)
JP2016523923A5 (enExample)
JP2013530237A5 (enExample)
JP2018519351A5 (enExample)
JP2020506171A5 (enExample)
JP2013521286A5 (enExample)
JP2017504635A5 (enExample)
JP2010095546A5 (enExample)
MA38323A1 (fr) Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale
MX2017013483A (es) Compuestos y su uso como inhibidores de ?-secretasa 1 (bace1).
JP2016532647A5 (enExample)
JP2015500223A5 (enExample)
JP2016522254A5 (enExample)
JP2017502092A5 (enExample)
JP2011005256A5 (enExample)